Nuwiq, Human cell line recombinant human factor VIII (Human-cl rhFVIII), 500IU, powder and solvent for solution for injection. Vial of powder and prefilled WFI syringe

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

simoctocog alfa, Quantity: 500 IU

Pieejams no:

Octapharma Australia Pty Ltd

SNN (starptautisko nepatentēto nosaukumu):

simoctocog alfa

Zāļu forma:

Injection, powder for

Kompozīcija:

Excipient Ingredients: arginine hydrochloride; poloxamer; calcium chloride dihydrate; sodium citrate dihydrate; sucrose; sodium chloride

Ievadīšanas:

Intravenous

Vienības iepakojumā:

1 vial

Receptes veids:

exempt from scheduling - Appendix A; prescription medicine

Ārstēšanas norādes:

Treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia A (congenital factor VIII deficiency). Nuwiq does not contain von Willebrand Factor and is thus not indicated to treat von Willebrand?s Disease.

Produktu pārskats:

Visual Identification: Nuwiq - white to off-white lyophilised powder,WFI - clear, colourless liquid; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Autorizācija statuss:

Licence status A

Autorizācija datums:

2014-11-10